Sickle Cell Anemia Clinical Trial
— SCAOfficial title:
Early Detection of Changes in Ventilatory Mechanics in Patients With Sickle Cell Anemia
Verified date | September 2015 |
Source | Rio de Janeiro State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Brazil: Ethics Committee |
Study type | Observational |
The Sickle Cell Anemia (SCA) is a recessive genetic condition, monogenic, resulting in
defects in the red cell structure. In the investigators' country, this disease affects about
3,000 children each year and is considered one of the most prevalent disorders among the
group of existing hereditary diseases.
The lungs are frequently affected in this disease by Acute Chest Syndrome (STA). Besides
being the leading cause of death and the second leading cause of hospitalization in SCA, the
STA is correlated with cognitive impairment frame these patients, resulting secondary Stroke
vaso-occlusion of capillaries that supply the brain tissue.
Traditional tests of pulmonary function allow assess whether the person has any commitment
in the respiratory system, whether obstructive, restrictive or mixed. To run these tests it
is necessary that the patient understands and performs a forced expiratory maneuver to
obtain reliable results. In the particular case of SCA, performing these tests it is very
difficult due to the presence of cognitive impairment of varying degrees. This results in
underdiagnosis of early changes in the lung parenchyma during the therapeutic window,
committing the proper monitoring and treatment offered to these patients.
Status | Completed |
Enrollment | 80 |
Est. completion date | August 2015 |
Est. primary completion date | July 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients older than 18 years - Typing of Hemoglobin SS Exclusion Criteria: - History absence of respiratory infections and hospitalized in the last three months - Asthma , smoking, rheumatological and oncological diseases, acute pain and inability to independent ambulation |
Observational Model: Case Control, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Rio de Janeiro State University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | spirometrics parameters of pulmonary function tests assessed by forced expiratory volume in one second (FEV1) | 1 day | No | |
Primary | spirometrics parameters of pulmonary function tests assessed by forced vital capacity (FVC) | 1 day | No | |
Primary | spirometrics parameters of pulmonary function tests assessed by ratio forced expiratory volume in one second and forced vital capacity (FEV1 / FVC) | 1 day | No | |
Primary | spirometrics parameters of pulmonary function tests assessed by FEF max (Flow Forced Expiratory maximum) | 1 day | No | |
Primary | plethysmographics parameters of pulmonary function tests assessed by Total Lung Capacity (TLC) | 1 day | No | |
Primary | plethysmographics parameters of pulmonary function tests assessed by functional residual capacity (FRC) | 1 day | No | |
Primary | plethysmographics parameters of pulmonary function tests assessed by residual volume (RV) | 1 day | No | |
Primary | plethysmographics parameters of pulmonary function tests assessed by Ratio Residual Volume and Total Lung Capacity (RV / TLC) | 1 day | No | |
Primary | plethysmographics parameters of pulmonary function tests assessed by Airway resistance (Rva) | 1 day | No | |
Primary | diffusion parameters of pulmonary function tests assessed by Diffusing Capacity Carbon monoxide (DLCO) | 1 day | No | |
Primary | diffusion parameters of pulmonary function tests assessed by VA (Volume Alveolar) | 1 day | No | |
Primary | diffusion parameters of pulmonary function tests assessed by diffusion coefficient (DLCO / VA) | 1 day | No | |
Primary | forced oscillation technique assessed by zero resistance at the intercept (R0) in cmH2O/l/s | 1 day | No | |
Primary | forced oscillation technique assessed by resistance at 4 Hz (Rrs4Hz) in cmH2O/l/s | 1 day | No | |
Primary | forced oscillation technique assessed by average resistance (Rm) in cmH2O/l/s | 1 day | No | |
Primary | reactive parameters of the forced oscillation technique assessed by mean reactance (Xm) in cmH2O/l/s is a parameter related to the inhomogeneity of the respiratory system | 1 day | No | |
Primary | reactive parameters of the forced oscillation technique of the respiratory system compliance was measured by dynamic compliance (Crs, dyn) in cmH2O | 1 day | No | |
Primary | reactive parameters of the forced oscillation technique of total mechanical loading of the respiratory system was assessed using the absolute value of the respiratory impedance (Z4Hz) in cmH2O/l/s | 1 day | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04581356 -
Voxelotor Sickle Cell Exercise Study
|
Phase 4 | |
Completed |
NCT02712346 -
The Role of Endothelin-1 in Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT01976416 -
Novel Use Of Hydroxyurea in an African Region With Malaria
|
Phase 3 | |
Withdrawn |
NCT02162225 -
Study of Beet Juice for Patients With Sickle Cell Anemia
|
Phase 2 | |
Completed |
NCT01137721 -
State Of The Art Functional Imaging In Sickle Cell Disease
|
||
Withdrawn |
NCT00937144 -
Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil
|
Phase 4 | |
Terminated |
NCT01350232 -
Treatment of Sickle Cell Anemia With Stem Cell Transplant
|
N/A | |
Completed |
NCT00512564 -
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Completed |
NCT00512226 -
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Completed |
NCT00004143 -
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
|
Phase 2 | |
Completed |
NCT00004412 -
Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
|
Phase 2 | |
Withdrawn |
NCT01925001 -
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
|
Phase 2 | |
Completed |
NCT01783990 -
Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol
|
||
Completed |
NCT01848691 -
Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis
|
N/A | |
Completed |
NCT00874172 -
Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy
|
N/A | |
Completed |
NCT01000155 -
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
|
Phase 2 | |
Completed |
NCT00236093 -
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
|
Phase 2 | |
Completed |
NCT00399074 -
Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia
|
Phase 3 | |
Completed |
NCT00004492 -
Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia
|
Phase 1/Phase 2 |